Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

WordPress Tables Plugin

Microcap biotech Imagion Biosystems (ASX:IBX), which focuses on the early detection of cancer, is on the winners list this morning after announcing that its MagSense HER2 imaging agent Phase 1 study (IBI10103) has achieved its enrolment target.

IBX said the study has been instrumental in revealing the potential clinical use of the MagSense HER2 Imaging Agent and confirmation that the company’s targeted nanoparticle technology has the potential to change how MRI can be used to specifically detect cancer.

“Completing the target enrolment numbers for the Phase 1 study is a great achievement for our first clinical study,” IBX CEO Bob Proulx said in an announcement.

Iris Metals (ASX:IR1) is back trading today after a trading halt and completing an oversubscribed $15 million capital raise at $1/share, including a one for two attaching option with an exercise price of $1.50, expiring two years from issue date.

The raise was cornerstoned by Waratah’s Electrification and Decarbonization AIE LP Fund with funds directed toward drilling and development of the recently acquired Beecher and Edison lithium Projects and exploration of the 2,387 BLM claims.


Stocks highlighted in yellow have made market-moving announcements (click headings to sort). 

WordPress Tables Plugin